Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

Clinical complete response of 43% seen for those with muscle-invasive bladder cancer receiving neoadjuvant gemcitabine, cisplatin, plus nivolumab

Related Keywords

New York , United States , Matthewd Galsky , , Icahn School Of Medicine At Mount Sinai , Healthday News , Icahn School , Mount Sinai , New York City ,